Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
macitentan + dapagliflozin
- Development stage
- Unknown
- Lead developer
- Gachon University Gil Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of macitentan and dapagliflozin and is being investigated by Gachon University Gil Medical Center for the treatment of combined pre- and post-capillary pulmonary hypertension (CpcPH) in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). Macitentan is a dual endothelin receptor antagonist (ERA) that blocks both endothelin A (ET-A) and endothelin B (ET-B) receptors, which helps to reduce pulmonary vascular resistance and improve hemodynamics. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys and has established cardiovascular benefits in heart failure management. The combination is currently being evaluated in a Phase 4 exploratory clinical trial to assess its efficacy and safety in this specific patient population.
- Brand names
- OpsumitForxigaFarxiga
- Other names
- Macitentan + Dapagliflozin in CpcPH-HF
02
Targets
EDNRB (Endothelin receptor type B)SGLT2 (Sodium-glucose cotransporter protein subunit 2)EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on macitentan + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on macitentan + dapagliflozin.